Torrent Pharmaceuticals (TORNTPHARM) Share Price Fall Streak Extends to Second Straight Session
- September 4, 2026
- Posted by: Harsh Piplani
- Category: News
Torrent Pharmaceuticals Share Price Fall Streak remained in focus on 04 September 2026 as the stock closed lower for its second straight session, taking the cumulative move across the streak to -3.57% from the streak start base price of Rs 5,004.4 on 2026-09-03. The stock ended at Rs 4,825.9, and the supplied data confirms this two-session pattern but does not establish a company-specific cause for the continued decline.
The latest session itself showed further downside from the previous close of Rs 4,924.7, with the stock opening at Rs 4,939.95, touching a day high of Rs 4,939.95 and a day low of Rs 4,825.75 before closing near the session bottom. Turnover stood at Rs 4.45 crore and market capitalisation was Rs 1,90,351.29 crore. For readers, a run of consecutive lower closes matters because it shows sustained weakness across more than one trading session rather than an isolated one-day move.
Torrent Pharmaceuticals (TORNTPHARM) Share Price Fall Streak: Consecutive Decline Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 4,825.9 |
| Previous Close | Rs 4,924.7 |
| Today's Move | -Rs 98.80 (-2.01%) |
| Open | Rs 4,939.95 |
| High | Rs 4,939.95 |
| Low | Rs 4,825.75 |
| Turnover | Rs 4.45 crore |
| Market Capitalisation | Rs 1,90,351.29 crore |
Torrent Pharmaceuticals Share Price Today reflected another session of weakness, with the stock falling Rs 98.8 or 2.01% from the previous close of Rs 4,924.7 to Rs 4,825.9. The session began at Rs 4,939.95, which also marked the intraday high, and then moved steadily lower to Rs 4,825.75. That left the close almost at the day low, showing that the downside pressure persisted through the session instead of reversing meaningfully into the close.
The one-day move also sits within the wider two-session pattern. From the streak start base price of Rs 5,004.4 on 2026-09-03, the stock has now declined 3.57% over the second straight session of lower closes. That is the key differentiator in this Torrent Pharmaceuticals Share Price Fall Streak story: the market is reacting to a continued pattern rather than a single downtick. With turnover at Rs 4.45 crore and market capitalisation at Rs 1,90,351.29 crore, the session drew attention because it came in a large listed pharmaceuticals company where consecutive lower closes are closely watched for near-term price behaviour.
What the Consecutive Declines Show
The two-session pattern shows that downside pressure has extended beyond one trading day, and that makes the current move more relevant than a standalone decline. In this Torrent Pharmaceuticals Share Price Fall Streak, the latest close came near the intraday low after the stock failed to hold its opening level, a sign that weakness remained present through the day.
There is also a mixed read in the available technical indicators. The RSI stands at 51.8, which is broadly neutral rather than deeply weak. The stock is trading below its 50-day moving average of Rs 4,945.77, indicating that recent momentum has softened, but it remains above its 200-day moving average of Rs 4,459.93, which shows the longer-term price structure is still above that reference level. In practical terms, the second straight session suggests readers should separate short-term weakness from the broader listed-company context and then examine whether valuation and profitability metrics justify the attention the stock is receiving.
Torrent Pharmaceuticals (TORNTPHARM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,90,351.29 crore |
| P/E Ratio | 85.89x |
| P/B Ratio | 20.87x |
| ROE | 26.76% |
| ROCE | 19.27% |
| EPS | Rs 57.34 |
| Book Value Per Share | Rs 235.97 |
| Dividend Yield | 0.77% |
Torrent Pharmaceuticals Fundamental Analysis offers a useful counterpoint to the recent decline. The company carries a market capitalisation of Rs 1,90,351.29 crore, placing it among the larger names in Indian pharmaceuticals by size. Its P/E ratio stands at 85.89 and the P/B ratio at 20.87, while return ratios remain strong with ROE at 26.76% and ROCE at 19.27%.
On per-share measures, EPS is Rs 57.34, which represents earnings attributable to each share, and book value is Rs 235.97 per share, showing the accounting net worth behind each share. Dividend yield is 0.77, which reflects the historical payout relative to the current market price. The combination is notable because it pairs high valuation multiples with strong profitability metrics. That does not explain the current decline, but it does explain why Torrent Pharmaceuticals Stock News attracts attention when the market price weakens for a second straight session: the stock is not a low-multiple name, so any shift in sentiment tends to be examined alongside valuation discipline and return ratios.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 85.89x |
| Benchmark Median P/E | 32.61x |
| Benchmark Average P/E | 48.83x |
| Benchmark P/E Range | 3.32x to 645.91x |
| Company P/B Ratio | 20.87x |
| Benchmark Median P/B | 2.89x |
| Benchmark Average P/B | 4.31x |
| Company ROE | 26.76% |
| Benchmark Median ROE | 11.79% |
| Benchmark Average ROE | 11.17% |
| Company ROCE | 19.27% |
| Benchmark Median ROCE | 13.66% |
| Benchmark Average ROCE | 13.7% |
| Company Market Capitalisation | Rs 1,90,351.29 crore |
| Benchmark Median Market Cap | Rs 730.27 crore |
| Benchmark Average Market Cap | Rs 14,155.46 crore |
The sector data shows Torrent Pharmaceuticals is being assessed against a large and diverse listed universe, and that makes the comparison especially relevant. Within the Healthcare sector and the Pharmaceuticals & Drugs industry, the benchmark scope is the same industry and covers 201 companies. Against that backdrop, Torrent Pharmaceuticals Share Price Fall Streak is unfolding in a sector where the company’s valuation and profitability both stand out numerically.
The company P/E of 85.89 is far above the industry median of 32.61 and average of 48.83 across 169 companies, while still within a broad range of 3.32 to 645.91. Its P/B of 20.87 is also above the industry median of 2.89 and average of 4.31 across 200 companies, within a range of -11.14 to 27.89. On profitability, ROE of 26.76% is stronger than the industry median of 11.79% and average of 11.17 across 200 companies, while ROCE of 19.27% is above the median of 13.66 and average of 13.7 across 200 companies. Market capitalisation of Rs 1,90,351.29 crore is well above the industry median of Rs 730.27 crore and average of Rs 14,155.46 crore, within a 201-company range of Rs 5.69 crore to Rs 4,63,791.45 crore.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,63,791.45 | 37.77 | 5.28 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,45,080.59 | 83.91 | 13.89 | 16.19 | 21.51 |
| Zydus Lifesciences | ZYDUSLIFE | 1,14,832.64 | 25.09 | 4.2 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,14,162.52 | 33.29 | 3.19 | 11.83 | 16 |
| Laurus Labs | LAURUSLABS | 1,00,660.17 | 92.52 | 17.94 | 18.31 | 18.2 |
Peer data shows where Torrent Pharmaceuticals sits within the upper tier of Indian pharmaceuticals. Sun Pharmaceutical Industries, with a market capitalisation of Rs 4,63,791.45 crore, is larger and trades at a lower P/E of 37.77 and P/B of 5.28, with ROE of 14.85% and ROCE of 19.11%. Divi’s Laboratories is also larger at Rs 2,45,080.59 crore and trades at 83.91 times earnings and 13.89 times book, with ROE of 16.19% and ROCE of 21.51%.
Against mid-sized large peers in the data set, Torrent’s valuation remains elevated. Zydus Lifesciences trades at a P/E of 25.09 and P/B of 4.2, Cipla at 33.29 and 3.19, and Laurus Labs at 92.52 and 17.94. Torrent’s ROE of 26.76% is higher than Sun Pharma, Divi’s, Zydus, Cipla and Laurus Labs, while its ROCE of 19.27% is above Sun Pharma, Cipla and Laurus Labs but below Divi’s and Zydus. So the peer picture is not one-dimensional: profitability is comparatively strong, but the valuation multiples remain richer than most of the selected peers, which is why the stock’s two-session decline is being scrutinised closely.
Why Investors Are Watching Torrent Pharmaceuticals
- The stock has closed lower for the second straight session, taking the cumulative two-day decline to 3.57% from Rs 5,004.4 to Rs 4,825.9.
- The latest close came near the day low of Rs 4,825.75 after opening at Rs 4,939.95, showing sustained intraday weakness.
- Valuation remains elevated at 85.89 times earnings and 20.87 times book, even as ROE stands at 26.76% and ROCE at 19.27%.
- The stock is below its 50-day moving average of Rs 4,945.77 but above its 200-day moving average of Rs 4,459.93, pointing to mixed trend context.
- Sector benchmarks show the company trades at materially higher valuation multiples than industry medians and averages across the same industry universe.
About the Company
Torrent Pharmaceuticals operates in the Healthcare sector and is part of the Pharmaceuticals & Drugs industry. In market terms, it sits among the larger listed companies in its industry, with a market capitalisation of Rs 1,90,351.29 crore. That size places it well above the industry median and average market capitalisation in the supplied benchmark set. For readers tracking company news and market positioning, the stock is relevant not only because of the current two-session decline, but also because it is being valued alongside some of the biggest and most closely followed pharmaceutical names in the same listed industry group.
Track Torrent Pharmaceuticals on Univest
On Univest, readers can track Torrent Pharmaceuticals Share Price Fall Streak alongside live market price moves, valuation ratios, moving averages, RSI, 52-week levels when available, sector benchmarks and peer metrics. Univest also helps place day-to-day stock updates in a wider context by showing how price action, company fundamentals and industry comparisons are changing over time for the same listed company.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Torrent Pharmaceuticals in focus today?
Ans. Torrent Pharmaceuticals is in focus because it closed lower for the second straight session. The stock ended at Rs 4,825.9, and the cumulative decline across the two-session streak now stands at 3.57% from Rs 5,004.4.
What happened in Torrent Pharmaceuticals shares on 04 September 2026?
Ans. On 04 September 2026, the stock fell Rs 98.8 or 2.01% from Rs 4,924.7 to Rs 4,825.9. It opened at Rs 4,939.95, hit a high of Rs 4,939.95 and a low of Rs 4,825.75.
Does the data show why Torrent Pharmaceuticals is falling?
Ans. The supplied data confirms the price pattern and the second straight session of lower closes, but it does not establish a company-specific cause for the move. That means the event is verified, while the catalyst is not identified here.
What does the two-session decline indicate?
Ans. A two-session decline indicates weakness that has extended beyond a single trading day. In this case, the stock has fallen 3.57% from the streak base price of Rs 5,004.4, making the move more notable than a one-day slip.
How is Torrent Pharmaceuticals valued versus its industry?
Ans. Torrent Pharmaceuticals trades at a P/E of 85.89 versus the same-industry median of 32.61 and average of 48.83. Its P/B of 20.87 is also above the industry median of 2.89 and average of 4.31.
Are Torrent Pharmaceuticals profitability ratios strong?
Ans. The supplied profitability ratios are strong relative to industry benchmarks. ROE stands at 26.76% versus the industry median of 11.79%, while ROCE is 19.27% versus the industry median of 13.66 across the same industry set.
How large is Torrent Pharmaceuticals in market capitalisation terms?
Ans. Torrent Pharmaceuticals has a market capitalisation of Rs 1,90,351.29 crore. That is far above the same-industry median of Rs 730.27 crore and average of Rs 14,155.46 crore in the supplied 201-company benchmark universe.
How does Torrent Pharmaceuticals compare with major listed peers?
Ans. Torrent Pharmaceuticals has a higher ROE than Sun Pharma, Divi's, Zydus, Cipla and Laurus Labs in the supplied peer set. But its P/E of 85.89 is above most peers, with only Laurus Labs higher at 92.52.
Track Torrent Pharmaceuticals (TORNTPHARM) Share Price on Univest
UseTorrent Pharmaceuticals (TORNTPHARM) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
